A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics
and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with
castration-resistant prostate cancer (CRPC).